---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-055815"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T20:51:27.076369+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cellectar reports Q1 net loss of $8.6M; cash at $12.7M with runway into Q4 2023

## Summary
- Net loss of ($8.6M) or ($0.76)/share vs ($6.1M) or ($1.00)/share in Q1 2022.
- Cash and equivalents $12.7M at March 31, 2023, down from $19.9M at Dec 31, 2022.
- R&D expense rose to $6.7M from $3.9M YoY on clinical, manufacturing costs.
- G&A expense decreased to $2.1M from $2.3M YoY driven by lower professional fees.
- Enrolling pivotal iopofosine trial in Waldenstrom's; topline data expected in 2023.

## SEC filing metadata
- accession: 0001104659-23-055815
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/0001104659-23-055815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/tm2314664d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-055815
- JSON: https://secwatch.observer/filing/0001104659-23-055815.json
- Plain text: https://secwatch.observer/filing/0001104659-23-055815.txt

## Key facts
- Earnings Releases
  Cellectar Biosciences, Inc. reported three months ended March 31, 2023 results: net income ($8.6) million, EPS ($0.76) per share.
  - Period: three months ended March 31, 2023
  - Net income: ($8.6) million
  - EPS: ($0.76) per share
  - Result: reported results
  source text: The net loss attributable to common stockholders for the three months ended March 31, 2023 was ($8.6) million, or ($0.76) per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1279704/000110465923055815/0001104659-23-055815-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.